On this episode of The Long View, Tom Idzorek, chief investment officer of retirement for Morningstar Investment Management ... one, I’ll turn to you. How does the inclusion of human capital ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

Rubric Capital Management LP boosted its position ... The company’s lead product candidates include zanidatamab, a human ...

Jacobs emphasized that one major trend for 2025 will be the acceleration of AI infrastructure and its integration into consumer issues. He outlined 3 distinct stages of the AI theme: the build phase, ...

Director Ecor1 Capital, Llc purchased 11,958 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The ...

DeVoe & Company survey suggests RIAs will have their work cut out for them around talent management. What should RIAs be ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug ...

Janus Henderson Investors and Logos Capital also participated. Existing investors include Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management ... in a Phase 1 healthy volunteer ...

From Prestige Estates to HSCL, Bajaj Broking has picked its top five stocks to buy in the new year for a 12 month investment.

Human genetics ... and Logos Capital participating alongside a roster of existing investors that includes Third Rock Ventures, ARCH Venture Partners and Matrix Capital Management, among others ...

The new model shows open-source closing in on closed-source models, suggesting reduced chances of one big AI player ruling the game.